Cargando…
Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
BACKGROUND AND AIMS: Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL qu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043221/ https://www.ncbi.nlm.nih.gov/pubmed/36998975 http://dx.doi.org/10.3389/fcvm.2023.1124660 |
_version_ | 1784913096721039360 |
---|---|
author | Kharoubi, Mounira Bézard, Mélanie Broussier, Amaury Galat, Arnault Gounot, Romain Poullot, Elsa Molinier-Frenkel, Valérie Fanen, Pascale Funalot, Benoit Itti, Emmanuel Lemonnier, François Sing Chadha, Gagan Deep Guendouz, Soulef Mallet, Sophie Zaroui, Amira Audard, Vincent Audureau, Etienne Le Corvoisier, Philippe Hittinger, Luc Planté Bordeneuve, Violaine Lefaucheur, Jean-Pascal Amiot, Aurélien Bequignon, Emilie Bartier, Sophie Leroy, Vincent Teiger, Emmanuel Oghina, Silvia Damy, Thibaud |
author_facet | Kharoubi, Mounira Bézard, Mélanie Broussier, Amaury Galat, Arnault Gounot, Romain Poullot, Elsa Molinier-Frenkel, Valérie Fanen, Pascale Funalot, Benoit Itti, Emmanuel Lemonnier, François Sing Chadha, Gagan Deep Guendouz, Soulef Mallet, Sophie Zaroui, Amira Audard, Vincent Audureau, Etienne Le Corvoisier, Philippe Hittinger, Luc Planté Bordeneuve, Violaine Lefaucheur, Jean-Pascal Amiot, Aurélien Bequignon, Emilie Bartier, Sophie Leroy, Vincent Teiger, Emmanuel Oghina, Silvia Damy, Thibaud |
author_sort | Kharoubi, Mounira |
collection | PubMed |
description | BACKGROUND AND AIMS: Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its prognostic value in CA. METHODS: A self-reported questionnaire, “Amylo-AFFECT” had been designed and validated for CA symptoms evaluation and screening by physicians. It was adapted here to assess HR-QoL (Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the theoretical model, internal consistency and convergent validity were assessed, particularly correlations between Amylo-AFFECT-QOL and the HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire. RESULTS: Amylo-AFFECT-QOL was completed by 515 patients, 425 of whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis (ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL evaluation was obtained with five dimensions: “Heart failure,” “Vascular dysautonomia,” “Neuropathy,” “Ear, gastrointestinal, and urinary dysautonomia,” and “Skin or mucosal involvement.” The global Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations (rs = 0.72, p < 0.05). Patients with a final diagnosis of CA had a global Amylo-AFFECT-QOL score significantly higher than the control group composed by patients with other diagnoses (22.2 ± 13.6 vs. 16.2 ± 13.8, respectively, p-value < 0.01). According to the Amylo-AFFECT-QOL global results, ATTRv patients’ QoL was more affected than AL patients’ QoL or ATTRwt patients’ QoL. Patients with a higher HR-QoL score had a greater risk of death or heart transplant after 1 year of follow-up (log-rank < 0.01). CONCLUSION: Amylo-AFFECT-QOL demonstrates good psychometric properties and is useful for quantifying HR-QoL and estimating CA prognosis. Its use may help to improve overall management of patients with CA. |
format | Online Article Text |
id | pubmed-10043221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100432212023-03-29 Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis Kharoubi, Mounira Bézard, Mélanie Broussier, Amaury Galat, Arnault Gounot, Romain Poullot, Elsa Molinier-Frenkel, Valérie Fanen, Pascale Funalot, Benoit Itti, Emmanuel Lemonnier, François Sing Chadha, Gagan Deep Guendouz, Soulef Mallet, Sophie Zaroui, Amira Audard, Vincent Audureau, Etienne Le Corvoisier, Philippe Hittinger, Luc Planté Bordeneuve, Violaine Lefaucheur, Jean-Pascal Amiot, Aurélien Bequignon, Emilie Bartier, Sophie Leroy, Vincent Teiger, Emmanuel Oghina, Silvia Damy, Thibaud Front Cardiovasc Med Cardiovascular Medicine BACKGROUND AND AIMS: Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its prognostic value in CA. METHODS: A self-reported questionnaire, “Amylo-AFFECT” had been designed and validated for CA symptoms evaluation and screening by physicians. It was adapted here to assess HR-QoL (Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the theoretical model, internal consistency and convergent validity were assessed, particularly correlations between Amylo-AFFECT-QOL and the HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire. RESULTS: Amylo-AFFECT-QOL was completed by 515 patients, 425 of whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis (ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL evaluation was obtained with five dimensions: “Heart failure,” “Vascular dysautonomia,” “Neuropathy,” “Ear, gastrointestinal, and urinary dysautonomia,” and “Skin or mucosal involvement.” The global Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations (rs = 0.72, p < 0.05). Patients with a final diagnosis of CA had a global Amylo-AFFECT-QOL score significantly higher than the control group composed by patients with other diagnoses (22.2 ± 13.6 vs. 16.2 ± 13.8, respectively, p-value < 0.01). According to the Amylo-AFFECT-QOL global results, ATTRv patients’ QoL was more affected than AL patients’ QoL or ATTRwt patients’ QoL. Patients with a higher HR-QoL score had a greater risk of death or heart transplant after 1 year of follow-up (log-rank < 0.01). CONCLUSION: Amylo-AFFECT-QOL demonstrates good psychometric properties and is useful for quantifying HR-QoL and estimating CA prognosis. Its use may help to improve overall management of patients with CA. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043221/ /pubmed/36998975 http://dx.doi.org/10.3389/fcvm.2023.1124660 Text en Copyright © 2023 Kharoubi, Bézard, Broussier, Galat, Gounot, Poullot, Molinier-Frenkel, Fanen, Funalot, Itti, Lemonnier, Sing Chadha, Guendouz, Mallet, Zaroui, Audard, Audureau, Le Corvoisier, Hittinger, Planté Bordeneuve, Lefaucheur, Amiot, Bequignon, Bartier, Leroy, Teiger, Oghina and Damy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Kharoubi, Mounira Bézard, Mélanie Broussier, Amaury Galat, Arnault Gounot, Romain Poullot, Elsa Molinier-Frenkel, Valérie Fanen, Pascale Funalot, Benoit Itti, Emmanuel Lemonnier, François Sing Chadha, Gagan Deep Guendouz, Soulef Mallet, Sophie Zaroui, Amira Audard, Vincent Audureau, Etienne Le Corvoisier, Philippe Hittinger, Luc Planté Bordeneuve, Violaine Lefaucheur, Jean-Pascal Amiot, Aurélien Bequignon, Emilie Bartier, Sophie Leroy, Vincent Teiger, Emmanuel Oghina, Silvia Damy, Thibaud Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis |
title | Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis |
title_full | Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis |
title_fullStr | Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis |
title_full_unstemmed | Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis |
title_short | Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis |
title_sort | amylo-affect-qol, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043221/ https://www.ncbi.nlm.nih.gov/pubmed/36998975 http://dx.doi.org/10.3389/fcvm.2023.1124660 |
work_keys_str_mv | AT kharoubimounira amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT bezardmelanie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT broussieramaury amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT galatarnault amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT gounotromain amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT poullotelsa amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT molinierfrenkelvalerie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT fanenpascale amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT funalotbenoit amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT ittiemmanuel amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT lemonnierfrancois amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT singchadhagagandeep amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT guendouzsoulef amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT malletsophie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT zarouiamira amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT audardvincent amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT audureauetienne amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT lecorvoisierphilippe amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT hittingerluc amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT plantebordeneuveviolaine amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT lefaucheurjeanpascal amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT amiotaurelien amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT bequignonemilie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT bartiersophie amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT leroyvincent amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT teigeremmanuel amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT oghinasilvia amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis AT damythibaud amyloaffectqolaselfreportedquestionnairetoassesshealthrelatedqualityoflifeandtodeterminetheprognosisincardiacamyloidosis |